Sequence: WEKLAKALAKALAKHLAKALAKALKA-NH2
| Experiment Id | EXP001419 |
|---|---|
| Paper | Mitochondrial transgene expression via an artificial mitochondrial DNA vector in cells from a patien |
| Peptide | KALA |
| Delivery Success Class | no |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | Surface display: STR-KALA 10 mol% of total lipids |
| Rna Concentration | 1 µg pDNA encapsulated in carrier in 50 µL HEPES buffer (pH 7.4) |
| Mixing Ratio | Protamine condensation N/P=2.3; final DNA concentration for packaging 35 µg/mL; lipid envelope DOPE/SM/CHEMS = 9:2:1 (molar ratio) lipid envelope around protamine-condensed pDNA; STR-KALA 10 mol% of total lipids |
| Formulation Format | KALA-MITO-Porter (liposome-based MITO-Porter modified with STR-KALA) |
| Formulation Components | Protamine-condensed pDNA core + lipid envelope (DOPE/SM/CHEMS = 9:2:1 (molar ratio) lipid envelope around protamine-condensed pDNA) + STR-KALA (10 mol%) |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | Mice (Balb/c used for biocompatibility evaluation in this study; serum markers at 24 h) |
| Administration Route | Intravenous (tail vein) |
| Output Type | Serum biochemical markers (AST, ALT, BUN, CRE, etc.) at 24 h post-injection |
| Output Value | |
| Output Units | |
| Output Notes | No substantial differences vs saline controls reported for serum biochemical markers after KALA-MITO-Porter administration. |
| Toxicity Notes | Biocompatibility assessment; no major marker elevations reported. |
| Curation Notes |